Impact of Domestic R&D Amortization on the Biotechnology Community

Background

- Previously, Section 174 of the Internal Revenue Code allowed businesses to deduct “research and experimentation” expenses in the same taxable year in which they occurred.

- The 2017 Tax Cuts and Jobs Act (TJCA) modified Section 174 so starting in 2022, businesses could no longer deduct such expenses in the same taxable year. Currently, businesses must amortize such deductions over five years for domestic expenditures or over 15 years for foreign expenditures.

Impact on Biotechnology Community

*Diminishes an already shrinking pool of capital available to small, early-stage biotech projects.*

- Biotech projects, such as drug developments, are lengthy, costly, and risky.

- This jump in upfront taxes occurs in an increasingly inhospitable investment environment. In 2022, venture capital investments in biotech slowed significantly, larger industry companies pulled or are rolling back funding partnerships with smaller biotechs, leaving small biotechs with increasingly limited fundraising opportunities in an already competitive field.

- Mandatory capitalization of R&D costs will divert much needed funding away from R&D to the payment of income taxes.
  - A larger upfront tax bill means large companies will have less funds to invest in the promising technologies being developed by smaller companies.
  - Even very small companies without a product on the market may find themselves with a tax liability as they can no longer use immediate expensing to fully offset payments from collaboration agreements, or for SBIR and similar grants. As small R&D intensive companies typically direct the majority of their funds into R&D, this new tax liability directly reduces the amount of resources they can devote to research.

- In terms of human health, a weakened biotech ecosystem threatens the short and long-term development of treatments for both chronic and rare diseases such as Alzheimer’s, Parkinson’s, obesity, cardiovascular, diseases with significant unmet need, and rare diseases.

Solution

The *American Innovation & Jobs Act of 2023* (S. 866) and the *American Innovation and R&D Competitiveness Act* (H.R. 2673), are bipartisan bills introduced on March 17, 2023 and April 18, 2023, by Senators Maggie Hassan (D-NH) and Todd Young (R-IN) and Representatives Ron Estes (R-KS) and John Larson (D-CT), would repeal this provision, restore the immediate expensing of research and development expenditures, removing what is essentially a tax on innovation.

Congress must take action to ensure small biotechs can resume investing maximal resources in critical R&D.